Want to see KR:249420 full AI Analyst Report?

Ildong Pharmaceutical Co., Ltd. (249420) Price & Analysis

― Followers

249420 Stock Chart & Stats

$12580.00

$10.00(0.08%)

Oct 30, 2026

―

Day’s Range― - ―

52-Week Range$11,250.00 - $45,050.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)122.64K

Market Cap

₩397.78B

Enterprise Value$605.83B

Total Cash (Recent Filing)₩60.37B

Total Debt (Recent Filing)₩142.05B

Price to Earnings (P/E)8.9

Beta0.28

Next Earnings

Nov 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.59%

Share Statistics

EPS (TTM)1418.03

Shares Outstanding31,638,252

10 Day Avg. Volume134,769

30 Day Avg. Volume122,643

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)4.69

Price to Sales (P/S)2.04

P/FCF Ratio218.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)872

Revenue Forecast (FY)₩597.50B

Bulls Say, Bears Say

Bulls Say

Profitability TurnaroundThe shift from substantial losses to positive and improving net income indicates that the turnaround is generating measurable earnings power. If maintained, this recovery can strengthen internal funding, support reinvestment, and improve resilience over the next several quarters.

Lower Leverage And Recovering ROEDeleveraging and expanded equity provide a stronger financial base than during the earlier loss period. Lower relative debt exposure should improve financial flexibility, while recovering ROE suggests capital is being used more productively as the earnings cycle improves.

Improved Cash GenerationThe return to positive operating and free cash flow is important because it provides evidence that the recovery is producing cash, not only accounting earnings. This supports debt servicing and investment capacity, although consistency will determine how durable the improvement is.

Bears Say

Negative Operating ProfitabilityNegative operating and EBITDA margins indicate that core operating performance remains under pressure even though reported net income is positive. This raises concerns about earnings quality and suggests that cost control or operating execution must improve before profitability can be considered durable.

Volatile Revenue PerformanceLarge swings in revenue make it harder to establish a dependable growth trajectory for the pharmaceutical and healthcare portfolio. Unstable top-line performance can reduce operating leverage, complicate planning, and make the recent earnings recovery more vulnerable to reversal.

Inconsistent Free-cash-flow ConversionWeak and uneven conversion of revenue and earnings into cash limits confidence in the quality of the recovery. Working-capital or timing effects may be influencing results, leaving less certainty that reported profitability will consistently translate into funds available for growth or balance-sheet improvement.

249420 FAQ

What was Ildong Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Ildong Pharmaceutical Co., Ltd. lowest stock price was $11250.00 and its highest was $45050.00 in the past 12 months.

What is Ildong Pharmaceutical Co., Ltd.’s market cap?

Ildong Pharmaceutical Co., Ltd.’s market cap is ₩397.78B.

When is Ildong Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Ildong Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 02, 2026 which is tomorrow.

How were Ildong Pharmaceutical Co., Ltd.’s earnings last quarter?

Ildong Pharmaceutical Co., Ltd. released its earnings results on Jul 30, 2026. The company reported $180.853 earnings per share for the quarter.

Is Ildong Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Ildong Pharmaceutical Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ildong Pharmaceutical Co., Ltd. pay dividends?

Ildong Pharmaceutical Co., Ltd. pays a Notavailable dividend of $200 which represents an annual dividend yield of 1.59%. See more information on Ildong Pharmaceutical Co., Ltd. dividends here

What is Ildong Pharmaceutical Co., Ltd.’s EPS estimate?

Ildong Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ildong Pharmaceutical Co., Ltd. have?

Ildong Pharmaceutical Co., Ltd. has 31,638,252 shares outstanding.

What happened to Ildong Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Ildong Pharmaceutical Co., Ltd. reported an EPS of $180.853 in its last earnings report. Following the earnings report the stock price went up 3.621%.

Which hedge fund is a major shareholder of Ildong Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in KR:249420

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ildong Pharmaceutical Co., Ltd.

Ildong Pharmaceutical Co., Ltd., established in 1941 and headquartered in Seoul, South Korea, is a company dedicated to the development, production, and distribution of a wide array of pharmaceutical products. Its extensive portfolio includes various medications such as anti-diarrheal agents, antibiotics, antifungals, antivirals, antihistamines, anticancer drugs, NSAIDs, and pain relievers, along with essential vitamins, minerals, and nutritional supplements. The company also produces treatments for numerous bodily systems, including cardiovascular, central nervous, dental, endocrine, gastrointestinal, respiratory, topical, and urogenital health, as well as those for blood circulation. Beyond pharmaceuticals, Ildong offers raw material drugs, health foods, cosmetics, and specialized medical devices, such as scar treatment products. Their range also extends to unique treatments for conditions like osteoarthritis, wound care, artificial tears, and feminine hygiene products. In addition to its product offerings, the company manages licenses and provides contract manufacturing services. With a global reach, Ildong Pharmaceutical exports its products to approximately 20 countries. Furthermore, the company has entered into a strategic collaboration with Evotec SE, leveraging Evotec's INDiGO platform to accelerate the development of its proprietary projects.